{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:37:05Z","timestamp":1782779825380,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-038"],"award-info":[{"award-number":["2021-I2M-1-038"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373745"],"award-info":[{"award-number":["82373745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Beijing","award":["7232256"],"award-info":[{"award-number":["7232256"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11393-2","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:48:20Z","timestamp":1762966100000},"page":"4421-4438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A potent and selective PROTAC degrader of CDK9 as effective inhibitor of HIV-1 RNA synthesis"],"prefix":"10.1007","volume":"30","author":[{"given":"Bo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"6","key":"11393_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15(6):122","journal-title":"Genome Biol"},{"issue":"4","key":"11393_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/trns.25146","volume":"4","author":"M Sanso","year":"2013","unstructured":"Sanso M, Fisher RP (2013) Pause, play, repeat: CDKs push RNAP ii\u2019s buttons. Transcription 4(4):146\u2013152","journal-title":"Transcription"},{"issue":"20","key":"11393_CR3","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1101\/gad.11.20.2622","volume":"11","author":"Y Zhu","year":"1997","unstructured":"Zhu Y, Pe\u2019ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH (1997) Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev 11(20):2622\u20132632","journal-title":"Genes Dev"},{"issue":"5","key":"11393_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1101\/gad.12.5.755","volume":"12","author":"J Peng","year":"1998","unstructured":"Peng J, Zhu Y, Milton JT, Price DH (1998) Identification of multiple Cyclin subunits of human P-TEFb. Genes Dev 12(5):755\u2013762","journal-title":"Genes Dev"},{"issue":"6","key":"11393_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.tips.2008.03.003","volume":"29","author":"S Wang","year":"2008","unstructured":"Wang S, Fischer PM (2008) Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 29(6):302\u2013313","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"11393_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1389450119666181026152221","volume":"20","author":"S Eyvazi","year":"2019","unstructured":"Eyvazi S, Hejazi MS, Kahroba H, Abasi M, Zamiri RE, Tarhriz V (2019) CDK9 as an appealing target for therapeutic interventions. Curr Drug Targets 20(4):453\u2013464","journal-title":"Curr Drug Targets"},{"issue":"12","key":"11393_CR7","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"DE MacCallum","year":"2005","unstructured":"MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by Inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65(12):5399\u20135407","journal-title":"Cancer Res"},{"issue":"10","key":"11393_CR8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW (2016) Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther 15(10):2273\u20132281","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"11393_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7):547\u2013566","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"11393_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, Pop-Damkov P, Su N, Roamio Franklin VN, Sekhar Reddy Chilamakuri C, D\u2019Santos CS, Shao W, Saeh JC, Koch R, Weinstock DM, Zinda M, Fawell SE, Drew L (2020) AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res 26(4):922\u2013934","journal-title":"Clin Cancer Res"},{"issue":"23","key":"11393_CR11","doi-asserted-by":"publisher","first-page":"15629","DOI":"10.1021\/acs.jmedchem.3c01233","volume":"66","author":"DB Freeman","year":"2023","unstructured":"Freeman DB, Hopkins TD, Mikochik PJ, Vacca JP, Gao H, Naylor-Olsen A, Rudra S, Li H, Pop MS, Villagomez RA, Lee C, Li H, Zhou M, Saffran DC, Rioux N, Hood TR, Day MAL, McKeown MR, Lin CY, Bischofberger N, Trotter BW (2023) Discovery of KB-0742, a Potent, Selective, orally bioavailable small molecule inhibitor of CDK9 for MYC-Dependent cancers. J Med Chem 66(23):15629\u201315647","journal-title":"J Med Chem"},{"issue":"2","key":"11393_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","volume":"37","author":"S Sher","year":"2023","unstructured":"Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R (2023) VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia 37(2):326\u2013338","journal-title":"Leukemia"},{"issue":"9","key":"11393_CR13","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1128\/JVI.72.9.7154-7159.1998","volume":"72","author":"K Fujinaga","year":"1998","unstructured":"Fujinaga K, Cujec TP, Peng J, Garriga J, Price DH, Grana X, Peterlin BM (1998) The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, Cyclin T1, and Tat. J Virol 72(9):7154\u20137159","journal-title":"J Virol"},{"issue":"20","key":"11393_CR14","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1101\/gad.11.20.2633","volume":"11","author":"HS Mancebo","year":"1997","unstructured":"Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y, Peng J, Blau C, Hazuda D, Price D, Flores O (1997) P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 11(20):2633\u20132644","journal-title":"Genes Dev"},{"issue":"7299","key":"11393_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature09131","volume":"465","author":"TH Tahirov","year":"2010","unstructured":"Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH (2010) Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465(7299):747\u2013751","journal-title":"Nature"},{"issue":"31","key":"11393_CR16","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1038\/sj.onc.1206785","volume":"22","author":"G Napolitano","year":"2003","unstructured":"Napolitano G, Mazzocco A, Fraldi A, Majello B, Lania L (2003) Functional inactivation of Cdk9 through oligomerization chain reaction. Oncogene 22(31):4882\u20134888","journal-title":"Oncogene"},{"key":"11393_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2015.08.012","volume":"123","author":"M Okamoto","year":"2015","unstructured":"Okamoto M, Hidaka A, Toyama M, Hosoya T, Yamamoto M, Hagiwara M, Baba M (2015) Selective Inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039. Antiviral Res 123:1\u20134","journal-title":"Antiviral Res"},{"issue":"5","key":"11393_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1128\/JVI.78.5.2517-2529.2004","volume":"78","author":"YL Chiu","year":"2004","unstructured":"Chiu YL, Cao H, Jacque JM, Stevenson M, Rana TM (2004) Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9\/CyclinT1). J Virol 78(5):2517\u20132529","journal-title":"J Virol"},{"issue":"13","key":"11393_CR19","doi-asserted-by":"publisher","first-page":"7208","DOI":"10.1073\/pnas.96.13.7208","volume":"96","author":"O Flores","year":"1999","unstructured":"Flores O, Lee G, Kessler J, Miller M, Schlief W, Tomassini J, Hazuda D (1999) Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proc Natl Acad Sci U S A 96(13):7208\u20137213","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"11393_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jcp.21938","volume":"222","author":"J Garriga","year":"2010","unstructured":"Garriga J, Xie H, Obradovic Z, Grana X (2010) Selective control of gene expression by CDK9 in human cells. J Cell Physiol 222(1):200\u2013208","journal-title":"J Cell Physiol"},{"issue":"10","key":"11393_CR21","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.celrep.2016.02.023","volume":"14","author":"J Campbell","year":"2016","unstructured":"Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ (2016) Large-Scale profiling of kinase dependencies in cancer cell lines. Cell Rep 14(10):2490\u20132501","journal-title":"Cell Rep"},{"issue":"1","key":"11393_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-022-01535-7","volume":"21","author":"C Nieto-Jimenez","year":"2022","unstructured":"Nieto-Jimenez C, Morafraile EC, Alonso-Moreno C, Ocana A (2022) Clinical considerations for the design of protacs in cancer. Mol Cancer 21(1):67","journal-title":"Mol Cancer"},{"issue":"19","key":"11393_CR23","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1002\/anie.201901336","volume":"58","author":"B Jiang","year":"2019","unstructured":"Jiang B, Wang ES, Donovan KA, Liang Y, Fischer ES, Zhang T, Gray NS (2019) Development of dual and selective degraders of Cyclin-Dependent kinases 4 and 6. Angew Chem Int Ed Engl 58(19):6321\u20136326","journal-title":"Angew Chem Int Ed Engl"},{"issue":"14","key":"11393_CR24","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1039\/D2CS00200K","volume":"51","author":"RG Guenette","year":"2022","unstructured":"Guenette RG, Yang SW, Min J, Pei B, Potts PR (2022) Target and tissue selectivity of PROTAC degraders. Chem Soc Rev 51(14):5740\u20135756","journal-title":"Chem Soc Rev"},{"issue":"12","key":"11393_CR25","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D (2019) A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25(12):1938\u20131947","journal-title":"Nat Med"},{"issue":"1","key":"11393_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem GM, Crews CM (2020) Proteolysis-Targeting chimeras as therapeutics and tools for biological discovery. Cell 181(1):102\u2013114","journal-title":"Cell"},{"issue":"1","key":"11393_CR27","doi-asserted-by":"publisher","first-page":"2169282","DOI":"10.1080\/14756366.2023.2169282","volume":"38","author":"B Yang","year":"2023","unstructured":"Yang B, Quan Y, Zhao W, Ji Y, Yang X, Li J, Li Y, Liu X, Wang Y, Li Y (2023) Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors. J Enzyme Inhib Med Chem 38(1):2169282","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"9","key":"11393_CR28","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1039\/D2CS00148A","volume":"51","author":"I Sosic","year":"2022","unstructured":"Sosic I, Bricelj A, Steinebach C (2022) E3 ligase ligand chemistries: from Building blocks to protein degraders. Chem Soc Rev 51(9):3487\u20133534","journal-title":"Chem Soc Rev"},{"issue":"54","key":"11393_CR29","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1039\/C7CC03879H","volume":"53","author":"CM Robb","year":"2017","unstructured":"Robb CM, Contreras JI, Kour S, Taylor MA, Abid M, Sonawane YA, Zahid M, Murry DJ, Natarajan A, Rana S (2017) Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) 53(54):7577\u20137580","journal-title":"Chem Commun (Camb)"},{"key":"11393_CR30","doi-asserted-by":"crossref","unstructured":"Tokarski RJ 2nd;, Sharpe CM, Huntsman AC, Mize BK, Ayinde OR, Stahl EH, Lerma JR, Reed A, Carmichael B, Muthusamy N, Byrd JC, Fuchs JR (2023) Bifunctional degraders of Cyclin dependent kinase 9 (CDK9): probing the relationship between linker length, properties, and selective protein degradation. Eur J Med Chem 254:115342","DOI":"10.1016\/j.ejmech.2023.115342"},{"issue":"18","key":"11393_CR31","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.1021\/acs.jmedchem.3c00828","volume":"66","author":"Y Zeng","year":"2023","unstructured":"Zeng Y, Xiao J, Xu Y, Wei F, Tian L, Gao Y, Chen Y, Hu Y (2023) Degradation of Cyclin-Dependent kinase 9\/Cyclin T1 by optimized Microtubule-Associated protein 1 light chain 3 Beta-Recruiting coumarin analogs. J Med Chem 66(18):12877\u201312893","journal-title":"J Med Chem"},{"key":"11393_CR32","doi-asserted-by":"publisher","first-page":"107876","DOI":"10.1016\/j.bioorg.2024.107876","volume":"153","author":"HJ Nie","year":"2024","unstructured":"Nie HJ, Li BF, Sun J, Yuan Y, Zhang ZG, Hu H, Wang WJ, Chen Z, Wang S, Huang W, Diao X, Yu J, Huang R, Chen XH (2024) Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer. Bioorg Chem 153:107876","journal-title":"Bioorg Chem"},{"key":"11393_CR33","doi-asserted-by":"publisher","first-page":"113091","DOI":"10.1016\/j.ejmech.2020.113091","volume":"211","author":"X Qiu","year":"2021","unstructured":"Qiu X, Li Y, Yu B, Ren J, Huang H, Wang M, Ding H, Li Z, Wang J, Bian J (2021) Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion. Eur J Med Chem 211:113091","journal-title":"Eur J Med Chem"},{"issue":"16","key":"11393_CR34","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","volume":"65","author":"J Li","year":"2022","unstructured":"Li J, Liu T, Song Y, Wang M, Liu L, Zhu H, Li Q, Lin J, Jiang H, Chen K, Zhao K, Wang M, Zhou H, Lin H, Luo C (2022) Discovery of Small-Molecule degraders of the CDK9-Cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J Med Chem 65(16):11034\u201311057","journal-title":"J Med Chem"},{"issue":"26","key":"11393_CR35","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K, Winkler JD, Crew AP, Crews CM, Coleman K (2016) G., PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A 113(26):7124\u20137129","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5\u20136","key":"11393_CR36","first-page":"253","volume":"8","author":"J Hou","year":"2022","unstructured":"Hou J, Wang J, Yang F, Xu T (2022) DIA-MS2pep: a library-free framework for comprehensive peptide identification from data-independent acquisition data. Biophys Rep 8(5\u20136):253\u2013268","journal-title":"Biophys Rep"},{"issue":"3","key":"11393_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.antiviral.2008.12.004","volume":"81","author":"JM Garcia","year":"2009","unstructured":"Garcia JM, Gao A, He PL, Choi J, Tang W, Bruzzone R, Schwartz O, Naya H, Nan FJ, Li J, Altmeyer R, Zuo JP (2009) High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay. Antiviral Res 81(3):239\u2013247","journal-title":"Antiviral Res"},{"key":"11393_CR38","doi-asserted-by":"publisher","first-page":"111866","DOI":"10.1016\/j.ejmech.2019.111866","volume":"185","author":"M Zhu","year":"2020","unstructured":"Zhu M, Ma L, Zhou H, Dong B, Wang Y, Wang Z, Zhou J, Zhang G, Wang J, Liang C, Cen S, Wang Y (2020) Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants. Eur J Med Chem 185:111866","journal-title":"Eur J Med Chem"},{"issue":"2","key":"11393_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/A:1025732728195","volume":"27","author":"Y Suzuki","year":"2003","unstructured":"Suzuki Y, Misawa N, Sato C, Ebina H, Masuda T, Yamamoto N, Koyanagi Y (2003) Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells. Virus Genes 27(2):177\u2013188","journal-title":"Virus Genes"},{"issue":"9","key":"11393_CR40","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1016\/j.apsb.2023.05.026","volume":"13","author":"C Hu","year":"2023","unstructured":"Hu C, Shen L, Zou F, Wu Y, Wang B, Wang A, Wu C, Wang L, Liu J, Wang W, Liu Q (2023) Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy. Acta Pharm Sin B 13(9):3694\u20133707","journal-title":"Acta Pharm Sin B"},{"issue":"24","key":"11393_CR41","doi-asserted-by":"publisher","first-page":"12619","DOI":"10.1128\/JVI.01696-10","volume":"84","author":"J Zhang","year":"2010","unstructured":"Zhang J, Li G, Ye X (2010) Cyclin T1\/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J Virol 84(24):12619\u201312627","journal-title":"J Virol"},{"issue":"10","key":"11393_CR42","doi-asserted-by":"publisher","first-page":"e1005950","DOI":"10.1371\/journal.ppat.1005950","volume":"12","author":"K Ren","year":"2016","unstructured":"Ren K, Zhang W, Chen X, Ma Y, Dai Y, Fan Y, Hou Y, Tan RX, Li E (2016) An epigenetic compound library screen identifies BET inhibitors that promote HSV-1 and \u2013\u20092 replication by bridging P-TEFb to viral gene promoters through BRD4. PLoS Pathog 12(10):e1005950","journal-title":"PLoS Pathog"},{"key":"11393_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.antiviral.2016.08.008","volume":"133","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Okuyama-Dobashi K, Murakami S, Chen W, Okamoto T, Ueda K, Hosoya T, Matsuura Y, Ryo A, Tanaka Y, Hagiwara M, Moriishi K (2016) Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation. Antiviral Res 133:156\u2013164","journal-title":"Antiviral Res"},{"issue":"Pt 7","key":"11393_CR44","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1099\/vir.0.030494-0","volume":"92","author":"S Feichtinger","year":"2011","unstructured":"Feichtinger S, Stamminger T, Muller R, Graf L, Klebl B, Eickhoff J, Marschall M (2011) Recruitment of Cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and Cyclin T1. J Gen Virol 92(Pt 7):1519\u20131531","journal-title":"J Gen Virol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11393-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:02:17Z","timestamp":1779537737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11393-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["11393"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11393-2","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}